July 24, 2018 - Diagnostic and consumer healthcare remote monitoring technology company Biotricity Inc. has completed the alpha version of its Bioflux 2.0 deep data diagnostic solution in accordance with U.S. Food and Drug Administration (FDA) arrhythmia diagnostic standards.
The company intends to leverage its new AI and deep data technology in arrhythmia analysis in its Bioflux 2.0 solution and focus on improved accuracy, faster diagnostics for patients, more efficient monitoring, and improved call center efficiency.
“We hope our deep data solution will eventually lead to near-instantaneous diagnostics, circumventing some of the current issues inherent in arrhythmia monitors, such as the delay that it takes for a physician to receive and analyze a patient report,” said Waqaas Al-Siddiq, founder and CEO of Biotricity. “If we have the ability to anticipate a problem early we may have the potential to send preventative or predictive alerts.”
Diagnostic failure rates are still relatively high with about 5 percent of adult patients misdiagnosed each year in the U.S. This totals more than 12 million people. Biotricity hopes to employ deep data science to increase the accuracy and efficiency of diagnostics, with the first implementation in its Bioflux 2.0 solution.
The company expects to complete software and hardware prototyping for its new solution and to file a FDA 510(k) clearance application by early 2019.
This device technology is part of a larger trend in remote ECG monitoring devices. Read more on these advances.
For more information: www.biotricity.com
August 15, 2024 
